Abstract
Background
Parkinson’s disease (PD) is characterized by severe motor and non-motor symptoms reducing patients’ quality of life (QoL). Instruments have been well established for QoL assessments in PD, including the EuroQol (EQ-5D), the Parkinson’s disease questionnaire (PDQ-39), or rather uncommon, like the WHOQOL-100. So far, the impact of variables has been investigated for each of these measures separately in different study populations, limiting the comparability of the results. Thus, this study compared the EQ-5D, PDQ-39, and the WHOQOL-100 (with its short-form WHOQOL-BREF) in the same study population.
Methods
Seventy-five PD outpatients were assessed in a prospective study, including disease severity according to Hoehn and Yahr stage (HY) and Unified Parkinson Disease Rating Scale (UPDRS). The Geriatric Depression Scale (GDS-15) screened for depression.
Results
Decreased QoL was found with all three instruments. In multivariate models, sex and treatment complications had an impact on QoL according to all three measures, while duration of PD and HY was not associated with QoL in any of them. Depression was relevant for the WHOQOL-100/WHOQOL-BREF and the PDQ-39, but not for the EQ-5D. The total variances explained by the WHOQOL-100, WHOQOL-BREF, PDQ-39, and the EQ-5D were 0.27, 0.34, 0.70, and 0.50, respectively.
Conclusions
The associations between clinical aspects of PD and QoL vary substantially among all three measures. Importantly, depression as a frequent comorbidity in PD is underestimated by the EQ-5D, but not by the PDQ-39 and the WHOQOL-100/WHOQOL-BREF. In turn, motor impairments are underestimated by the latter and associated strongest with QoL in the EQ-5D.
Similar content being viewed by others
References
De Rijk M, Tzourio C, Breteler M et al (1997) Prevalence of parkinsonism and Parkinson’s disease in Europe: the EUROPARKINSON collaborative study. J Neurol Neurosurg Psychiatr 62:10–15
Bach J-P, Riedel O, Klotsche J, Spottke A, Dodel R, Wittchen H-U (2012) Impact of complications and comorbidities on treatment costs and health-related quality of life in patients with Parkinson’s disease. J Neurol Sci 314:41–47
Reuter I, Ebersbach G (2012) Efficacy of exercise in Parkinson’s Disease. Akt Neurol 39:236–247
The WHOQOL Group (1998) The World Health Organization quality of life assessment (WHOQOL): development and general psychometric properties. Soc Sci Med 46:1569–1585
Martinez-Martin P, Jeukens-Visser M, Lyons KE et al (2011) Health-related quality-of-life scales in Parkinson’s disease: critique and recommendations. Mov Disord 26:2371–2380
Chen FP, Chang CM, Shiu JH et al (2015) A clinical study of integrating acupuncture and western medicine in treating patients with Parkinson’s Disease. Am J Chin Med 43:407–423
Hendred SK, Foster ER (2016) Use of the World Health Organization quality of life assessment short version in mild to moderate Parkinson Disease. Arch Phys Med Rehab 97:2123–2129
Hirayamau MS, Gobbi S, Gobbi LTB, Stella F (2008) Quality of life (QoL) in relation to disease severity in Brazilian Parkinson’s patients as measured using the WHOQOL-BREF. Arch Gerontol Geriatr 46:147–160
Schestatsky P, Zanatto VC, Margis R et al (2006) Quality of life in a Brazilian sample of patients with Parkinson’s disease and their caregivers. Rev Bras Psiquiatr 28:209–211
Valeikiene V, Ceremnych J, Alekna V, Jumulynasam A (2008) Differences in WHOQOL-100 domain scores in Parkinson’s disease and osteoarthritis. Med Sci Mon 14:CR221–CR227
Hughes A, Daniel S, Kilford L, Lees A (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatr 55:181–184
Balzer-Geldsetzer M, Braga da Costa AS, Kronenbürger M (2011) Parkinson’s disease and dementia: a longitudinal study (DEMPARK). Neuroepidemiol 37:168–176
Hoehn M, Yahr M (1967) Parkinsonism: onset, progression and mortality. Neurol 17:427–442
Fahn S (1987) Unified Parkinson’s disease rating scale. In: Fahn S, Calne D (eds) Recent developments in Parkinson’s Disease. MacMillan Healthcare Information, Florham Park, pp 153–163
Folstein M, Folstein S, McHugh P (1975) Mini-Mental state: a practical method for grading the mental state of patients by the clinician. J Psychiatr Res 12:189–198
Kalbe E, Calabrese P, Kohn N et al (2008) Screening for cognitive deficits in Parkinson’s disease with the Parkinson neuropsychometric dementia assessment (PANDA) instrument. Parkinsonism Relat Disord 14:93–101
Petersen RC (2004) Mild cognitive impairment as a diagnostic entity. J Int Med 256:183–194
Emre M, Aarsland D, Brown R et al (2007) Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 22:1689–1707
Yesavage J, Brink T, Rose T et al (1983) Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 17:37–49
Schrag A, Barone P, Brown R et al (2007) Depression rating scales in Parkinson’s disease: critique and recommendations. Movement Disord 22:1077–1092
Brooks R (1996) Euroqol—the current state of play. Health Pol (Amst) 37:53–72
Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N (1997) The Parkinson’s disease questionnaire (PDQ-39): development and validation of a Parkinson’s disease summary index score. Age Ageing 26:353–357
Greiner W, Claes C, Busschbach J, von der Schulenburg J (2005) Validating the EQ-5D with time trade off for the German population. Eur J Health Econ 6:123–130
Peto V, Jenkinson C, Fitzpatrick R, Greenhall R (1995) The development and validation of a short measure of functioning and well-being for individuals with Parkinson’s disease. Qual Life Res 4:241–248
Angermeyer MC, Kilian R, Matschinger (2000) WHOQOL-100 und WHQOL-BREF. Hogrefe, Göttingen
Masthoff ED, Trompenaars FJ, Van Heck GL, Hodiamont PP, De Vries J (2005) Validation of the WHO quality of life assessment instrument (WHOQOL-100) in a population of Dutch adult psychiatric outpatients. Eur Psychiatr 20:465–473
Klotsche J, Minden K, Thon A, Ganser G, Urban A, Horneff G (2014) Improvement in health-related quality of life for children with juvenile idiopathic arthritis after start of treatment with etanercept. Arthr Care Res 66:253–262
Alonso J, Ferrer M, Gandek B et al (2004) Health-related quality of life associated with chronic conditions in eight countries: results from the International Quality of Life Assessment (IQOLA) Project. Qual Life Res 13:283–298
da Rocha NS, Fleck MP (2019) Evaluation of quality of life in adults with chronic health conditions: the role of depressive symptoms. Rev Brasil Psiquiatr 32:119–124
van Uem JMT, Marinus J, Canning C et al (2016) Health-related quality of life in patients with Parkinson’s disease a systematic review based on the ICF model. Neurosci Biobehav Rev 61:26–34
Lucas-Carrasco R, Pascual-Sedano B, Galan I, Kulisevsky J, Sastre-Garriga J, Gomez-Benito J (2011) Using the WHOQOL-DIS to measure quality of life in persons with physical disabilities caused by neurodegenerative disorders. Neurodegen Dis 8:178–186
König H, Bernert S, Angermeyer M (2005) Health status of the German population: results of a representative survey using the EuroQol questionnaire. Gesundheitswesen 67:173–182
Schrag A, Jahanshahi M, Quinn N (2000) How does Parkinson’s disease affect quality of life? A comparison with quality of life in the general population. Mov Disord 15:1112–1118
Abboud H, Genc G, Thompson NR et al (2017) Predictors of functional and quality of life outcomes following deep brain stimulation surgery in Parkinson’s disease patients: DISEASE, patient, and surgical Factors. Parkinsons Dis 2017:5609163. https://doi.org/10.1155/2017/5609163
Bettecken K, Bernhard F, Sartor J et al (2017) No relevant association of kinematic gait parameters with health-related quality of life in Parkinson’s disease. Plos One 12:e0176816
Lindgren HIV, Qvarfordt P, Bergman S, Gottsater A, Swedish Endovasc Claudication S (2018) Primary stenting of the superficial femoral Artery in patients with intermittent claudication has durable effects on health-related quality of life at 24 months: results of a randomized controlled trial. Cardiovasc Intervent Radiol 41:872–881
Den Oudsten BL, Van Heck GL, De Vries J (2007) The suitability of patient-based measures in the field of Parkinson’s disease: a systematic review. Mov Disord 22:1390–1401
Acknowledgements
Data were generated within the LANDSCAPE study (Representatives of the participating centers are: K. Reetz, Department of Neurology, RWTH Aachen University, Aachen; JARA—Translational Brain Medicine, Jülich and Aachen; A. Spottke, Department of Neurology, University of Bonn, and German Center for Neurodegenerative Diseases, Bonn; Department of Psychiatry, University of Bonn, Bonn, and German Center for Neurodegenerative Diseases, DZNE, Bonn; (A) Storch, Department of Neurology, University Medical Center Rostock; S. Baudrexel, Department of Neurology, Goethe University, Frankfurt/Main; (B) Mollenhauer, Paracelsus-Elena-Klinik, Kassel; Institute of Neuropathology, University Medical Center Goettingen, Goettingen; D. Berg, Department of Neurology, UKSH Campus Kiel, Kiel; I. Liepelt, Department of Neurodegenerative Diseases and Hertie Institute for Clinical Brain Research, University of Tuebingen, and German Center for Neurodegenerative Diseases, Tuebingen; J. Kassubek, Department of Neurology, University of Ulm; E. Kalbe, Department of Medical Psychology, University Clinic Cologne; H.U. Wittchen, Institute of Clinical Psychology and Psychotherapy, Technische Universitaet Dresden, Dresden). The LANDSCAPE study is part of the Competence Network Degenerative Dementias (KNDD) which was funded by the German Federal Ministry of Education and Research (project number 01GI1008C).
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Conflicts of interest
All authors declare that they have no conflicts of interests.
Ethical standards
The DEMPARK/LANDSCAPE study was approved by the Ethics Committee of Philipps University of Marburg (approval numbers 178/07 and 25/11) and, subsequently, by the local ethics committees of the participating centers. Written informed consent was obtained from all the participants before study entry.
Additional information
The members of LANDSCAPE Consortium are listed in the Acknowledgements section.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Balzer-Geldsetzer, M., Klotsche, J., LANDSCAPE Consortium. et al. Quality of life in a German cohort of Parkinson’s patients assessed with three different measures. J Neurol 265, 2713–2722 (2018). https://doi.org/10.1007/s00415-018-9047-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-018-9047-9